NEW YORK (AP) — Aretha Franklin will sing in honor of Elton John before she retires later this year.John announced Tuesday that the Queen of Soul will perform at his annual AIDS charity event on Nov. 7 at the Cathedral of St. John the Divine in New York. This year marks the Elton John AIDS Foundation's 25th year.Former President Bill Clinton, New York Gov. Andrew Cuomo and Sharon Stone will pay tribute to John's work as a philanthropist and humanitarian.Franklin said this year that she plans to retire and is working on a new album. The 74-year-old said after retiring she will perform at "some select things.
NYS Entity Status
NYS Filing Date
APRIL 23, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - ELTON CROSSING DEVELOPER LLC
Around the Web
- Aretha Franklin to perform at Elton John's AIDS gala
Tuesday Sep 12, 2017
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- New Development: Soft in the Middle, Splashy Up Top
By STEFANOS CHEN - Friday Sep 15, 2017
The luxury market in New York is pulling in two directions, with developers betting on big-ticket palatial aeries and million-dollar “starter” homes.
- Fit City: Taking Night-Life Cue, Gyms Lower the Lights
By TATIANA BONCOMPAGNI - Tuesday Jun 13, 2017
Cycling, boxing and running studios, as well as some full-service gyms, are using sophisticated lighting systems to heighten the exercise experience.
- Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
By Ben Fidler - Tuesday Sep 12, 2017
Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]